Furthermore, the selective inhibition of DDR2 effectively hinders breast cancer metastasis-associated TA-MSCs from depositing collagen type I, thereby reducing their capacity to facilitate breast cancer progression [20]. Here, DDR2 is linked to breast carcinoma.